Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia 18Burkitt Lymphoma 11Lymphoma 10Leukemia, Biphenotypic, Acute 7Lymphoma, Extranodal NK-T-Cell 5Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Dendritic Cell Sarcoma, Interdigitating 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Thrombocytopenia 1Recurrence 1Neutropenia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Vincristine 2Methotrexate 2Mercaptopurine 2Hydrocortisone 2Cytarabine 2prednylidene 1pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Prednisolone 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Epirubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Down Syndrome × Asparaginase × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡